142 related articles for article (PubMed ID: 38206455)
1. Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial.
Jackson D; Jenkins M; de Nigris E; Purkayastha D; Patel M; Ouwens M
Qual Life Res; 2024 Apr; 33(4):1029-1039. PubMed ID: 38206455
[TBL] [Abstract][Full Text] [Related]
2. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease.
Solem CT; Sun SX; Sudharshan L; Macahilig C; Katyal M; Gao X
Int J Chron Obstruct Pulmon Dis; 2013; 8():641-52. PubMed ID: 24376348
[TBL] [Abstract][Full Text] [Related]
3. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.
Lin FJ; Pickard AS; Krishnan JA; Joo MJ; Au DH; Carson SS; Gillespie S; Henderson AG; Lindenauer PK; McBurnie MA; Mularski RA; Naureckas ET; Vollmer WM; Lee TA;
BMC Med Res Methodol; 2014 Jun; 14():78. PubMed ID: 24934150
[TBL] [Abstract][Full Text] [Related]
4. Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis.
Guo J; Chen Y; Zhang W; Tong S; Dong J
Int J Surg; 2020 Jun; 78():28-35. PubMed ID: 32304896
[TBL] [Abstract][Full Text] [Related]
5. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference.
Nolan CM; Longworth L; Lord J; Canavan JL; Jones SE; Kon SS; Man WD
Thorax; 2016 Jun; 71(6):493-500. PubMed ID: 27030578
[TBL] [Abstract][Full Text] [Related]
6. Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Xia Q; Zhao T; Palmer AJ
Qual Life Res; 2023 Dec; 32(12):3373-3387. PubMed ID: 37522942
[TBL] [Abstract][Full Text] [Related]
7. Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study.
Hoogendoorn M; Jowett S; Dickens AP; Jordan R; Enocson A; Adab P; Versteegh M; Mölken MR
Value Health; 2021 Nov; 24(11):1667-1675. PubMed ID: 34711368
[TBL] [Abstract][Full Text] [Related]
8. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
9. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
10. Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease.
Bae E; Choi SE; Lee H; Shin G; Kang D
BMC Pulm Med; 2020 Mar; 20(1):73. PubMed ID: 32293387
[TBL] [Abstract][Full Text] [Related]
11. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ.
Menn P; Weber N; Holle R
Health Qual Life Outcomes; 2010 Apr; 8():39. PubMed ID: 20398326
[TBL] [Abstract][Full Text] [Related]
13. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
14. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.
Rhodes K; Jenkins M; de Nigris E; Aurivillius M; Ouwens M
BMC Med Res Methodol; 2022 May; 22(1):150. PubMed ID: 35614467
[TBL] [Abstract][Full Text] [Related]
15. Comparison of EQ-5D-5L and SPVU-5D for measuring quality of life in patients with venous leg ulcers in an Australian setting.
Cheng Q; Kularatna S; Lee XJ; Graves N; Pacella RE
Qual Life Res; 2019 Jul; 28(7):1903-1911. PubMed ID: 30778889
[TBL] [Abstract][Full Text] [Related]
16. Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings.
Shiroiwa T; Noto S; Fukuda T
Value Health; 2021 Aug; 24(8):1193-1202. PubMed ID: 34372985
[TBL] [Abstract][Full Text] [Related]
17. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
[TBL] [Abstract][Full Text] [Related]
18. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
[TBL] [Abstract][Full Text] [Related]
19. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D.
Cox IA; Campbell J; de Graaff B; Otahal P; Corte TJ; Moodley Y; Hopkins P; Macansh S; Walters EH; Palmer AJ
Qual Life Res; 2023 Feb; 32(2):473-493. PubMed ID: 35927542
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life among Indian population: The EQ-5D population norms for India.
Jyani G; Prinja S; Garg B; Kaur M; Grover S; Sharma A; Goyal A
J Glob Health; 2023 Feb; 13():04018. PubMed ID: 36799239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
